Kaziani Katerina, Vassiliou Alice G, Kotanidou Anastasia, Athanasiou Chariclea, Korovesi Ioanna, Glynos Konstantinos, Orfanos Stylianos E
First Department of Critical Care Medicine and Pulmonary Services, GP Livanos and M Simou Laboratories, Evangelismos Hospital, Medical School of the National and Kapodistrian University of Athens, Athens, Greece.
5th Department of Internal Medicine and Infectious Diseases Unit, Evangelismos Hospital, Athens, Greece.
Infect Dis Ther. 2018 Mar;7(Suppl 1):15-25. doi: 10.1007/s40121-018-0192-3. Epub 2018 Mar 16.
Pulmonary capillary endothelium-bound (PCEB) angiotensin-converting enzyme (ACE) activity is a direct and quantifiable index of pulmonary endothelial function that decreases early in acute respiratory distress syndrome (ARDS) and correlates with its severity. Endothelial dysfunction is a major pathophysiology that underlies sepsis-related ARDS. Recombinant human activated protein C (rhAPC), now withdrawn from the market, has been used in the recent past as an endothelial-protective treatment in patients with septic organ dysfunction.
We investigated the effect of rhAPC on pulmonary endothelial function in 19 septic patients suffering from ARDS. Applying indicator-dilution type techniques, we measured single-pass transpulmonary percent metabolism (%M) and hydrolysis (v) of the synthetic, biologically inactive, and highly specific for ACE substrate, H-benzoyl-Phe-Ala-Pro (BPAP), under first-order reaction conditions, and calculated lung functional capillary surface area before and after treatment with rhAPC.
Pulmonary endothelium ACE activity was severely impaired in septic patients with ARDS, and was not affected by rhAPC treatment. Additionally, poor outcome was related to a more profound decrease in PCEB-ACE activity. Angiotensin-converting enzyme-substrate utilization was statistically significantly lower in non-survivors as compared to survivors, with no changes over time within each group: BPAP %M: 32.7 ± 3.4% at baseline to 25.6 ± 2.9% at day 7 in survivors versus 20.8 ± 2.8 to 15.5 ± 5%, respectively, in non-survivors (p = 0.044), while hydrolysis (v): 0.41 ± 0.06 at baseline to 0.30 ± 0.04 at day 7 in survivors compared to 0.24 ± 0.04 to 0.18 ± 0.06, respectively, in non-survivors (p = 0.049).
rhAPC administration in septic patients with ARDS did not improve PCEB-ACE activity indices. However, these indices might be useful in the early recognition of septic patients with ARDS at high risk of mortality.
肺毛细血管内皮结合(PCEB)的血管紧张素转换酶(ACE)活性是肺内皮功能的直接且可量化指标,在急性呼吸窘迫综合征(ARDS)早期会降低,并与其严重程度相关。内皮功能障碍是脓毒症相关ARDS的主要病理生理学基础。重组人活化蛋白C(rhAPC)现已退市,过去曾用于脓毒症器官功能障碍患者的内皮保护治疗。
我们研究了rhAPC对19例患有ARDS的脓毒症患者肺内皮功能的影响。应用指示剂稀释型技术,我们在一级反应条件下测量了合成的、无生物活性且对ACE底物高度特异性的H-苯甲酰基-Phe-Ala-Pro(BPAP)的单次经肺代谢百分比(%M)和水解(v),并计算了rhAPC治疗前后的肺功能性毛细血管表面积。
患有ARDS的脓毒症患者肺内皮ACE活性严重受损,且不受rhAPC治疗的影响。此外,不良预后与PCEB-ACE活性更显著降低有关。与幸存者相比,非幸存者的血管紧张素转换酶底物利用率在统计学上显著更低,每组内随时间无变化:幸存者基线时BPAP %M为32.7±3.4%,第7天为25.6±2.9%,而非幸存者分别为20.8±2.8至15.5±5%(p = 0.044),水解(v):幸存者基线时为0.41±0.06,第7天为0.30±0.04,而非幸存者分别为0.24±0.04至0.18±0.06(p = 0.049)。
在患有ARDS的脓毒症患者中给予rhAPC并不能改善PCEB-ACE活性指标。然而,这些指标可能有助于早期识别有高死亡风险的ARDS脓毒症患者。